A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update

被引：0
|
作者：
Ahn, M-j.
Cho, B. C. [1 ]
Kim, T. M. [2 ]
Han, J-y.
Kim, C. [3 ]
Shim, B. [4 ]
Drilon, A. [5 ,6 ]
Blumenschein, G. [7 ]
Villaruz, L. [8 ]
Gray, J. E. [9 ]
Pujol, J-l. [10 ]
Lena, H. [11 ]
Moro-Sibilot, D. [12 ]
Perez, J. [13 ]
Modi, D. A. [13 ]
Park, J. S. [13 ]
Patel, S. [13 ]
Li, S. [13 ]
Kim, E. [13 ]
Magnan, H. [13 ]
机构：
[1] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[3] Georgetown Univ, Med Oncol, Hematol Oncol, Washington, DC USA
[4] Catholic Univ Korea, Dept Med Oncol, Seoul, South Korea
[5] Weill Cornell Med Ctr, Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Weill Cornell Med Ctr, New York, NY USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[8] Univ Pittsburgh Med Ctr UPMC, Hillman Canc Ctr, Dept Oncol, Pittsburgh, PA USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol, Tampa, FL USA
[10] Ctr Hosp Reg Univ CHRU Montpellier Arnaud Villeneu, Dept Thorac & Vasc Surg, Montpellier, France
[11] Univ Rennes, Dept Oncol, Rennes, France
[12] Ctr Hosp Univ Grenoble, F-38000 Grenoble, France
[13] Regeneron Pharmaceut Inc, Med Oncol, Tarrytown, NY USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.754
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
721TiP
引用
收藏
页码：S1673 / S1674
页数：2
相关论文
共 50 条
  • [1] METxMET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
    Cho, B. C.
    Ahn, M-J.
    Kim, T. M.
    Kim, S-W.
    Han, J-Y.
    Kim, C.
    Shim, B.
    Ricordel, C.
    Drilon, A. E.
    Pujol, J-L.
    Gray, J. E.
    Villaruz, L.
    Blumenschein, G.
    Perez, J.
    Modi, D. A.
    Kaul, M.
    Patel, S.
    Hao, Y.
    Kim, E.
    Magnan, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S828 - S829
  • [2] A phase I/II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced non-small cell lung cancer (NSCLC).
    Rowlands, Tracey
    Boyapati, Anita
    Li, Siyu
    Daly, Christopher
    Seebach, Frank A.
    Lowy, Israel
    Rietschel, Petra
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] PHARMACOKIN ETICS (PK) AND SOLUBLE MET (SMET) PHARM ACODYNAMICS (PD) OF REGN5093, A MET X MET BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
    Masinde, S.
    Krishna, R.
    Paccaly, A.
    Irvin, S.
    Fraser, S.
    Retter, M.
    Magnan, H.
    Navas, T.
    Davis, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S67 - S67
  • [4] Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study
    Cho, B. C.
    Ahn, M-J.
    Kim, T. M.
    Kim, C.
    Shim, B. Y.
    Han, J-Y.
    Drilon, A. E.
    Lena, H.
    Gomez, J. E.
    Gray, J. E.
    Awad, M.
    Perez, J.
    Navas, M.
    Kaul, M.
    Patel, S.
    Gao, B.
    Magnan, H.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1085 - S1085
  • [5] Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer
    Navas, T.
    Drilon, A. E.
    Cho, B. C.
    Viau, J.
    Tao, W.
    Zhu, Y. O.
    Giangreco, N.
    Perez, J.
    Masinde, S.
    Paccaly, A.
    Krishna, R.
    Li, Y.
    Li, S.
    Daly, C.
    Patel, S.
    Laughlin, M.
    Seebach, F.
    Pouliot, J. F.
    Rietschel, P.
    Magnan, H.
    Boyapati, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S247 - S247
  • [6] Phase I/II trial of bortezimib and pemetrexed in patients with advanced non-small cell lung cancer
    Natale, R. B.
    McKinley, M.
    Hilger, J.
    Myers, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer
    Grunberg, SM
    Dugan, MC
    Greenblatt, MS
    Ospina, DJ
    Valentine, JW
    CANCER INVESTIGATION, 2005, 23 (05) : 392 - 398
  • [8] Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC).
    Williams, CC
    Haura, EB
    Antonia, SJ
    Chiappori, A
    Bepler, G
    Simon, GR
    Moffitt, HL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
  • [9] Phase II study of dasatinib in patients with advanced non-small cell lung cancer
    Johnson, F. M.
    Bekele, B. N.
    Feng, L.
    Wistuba, I. I.
    Tang, X.
    Tran, H. T.
    Erasmus, J. J.
    Hwang, L.
    Takebe, N.
    Stewart, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
    Govindan, R
    Lim, WT
    Arquette, MA
    Goodner, SA
    Fears, CL
    Mortimer, JE
    Fracasso, PM
    ONCOLOGY REPORTS, 2006, 15 (01) : 123 - 127
12345